Dana Pizzuti Crinetics Pharmaceuticals, Inc. (CRNX) insider trading activity

Dana Pizzuti is Chief Med and Dev Officer of Crinetics Pharmaceuticals, Inc.. Currently has a direct ownership of 66,837 shares of CRNX, which is worth approximately $2.91 Million. The most recent transaction as insider was on Dec 01, 2025, when has been sold 5,000 shares (Common Stock) at a price of $45.02 per share, resulting in proceeds of $225,100. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 66.8K

0.86% 3M change

128.52% 12M change

Total Value Held $2.91 Million

Dana Pizzuti Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 01 2025	SELL Open market or private sale	$225,100 $45.02 p/Share	5,000 Reduced 6.96%	66,837 Common Stock
Dec 01 2025	BUY Exercise of conversion of derivative security	$84,450 $16.89 p/Share	5,000 Added 6.51%	71,837 Common Stock
Nov 03 2025	SELL Open market or private sale	$214,800 $42.96 p/Share	5,000 Reduced 7.02%	66,270 Common Stock
Nov 03 2025	BUY Exercise of conversion of derivative security	$84,450 $16.89 p/Share	5,000 Added 6.56%	71,270 Common Stock
Oct 01 2025	SELL Open market or private sale	$209,050 $41.81 p/Share	5,000 Reduced 7.02%	66,270 Common Stock
Oct 01 2025	BUY Exercise of conversion of derivative security	$84,450 $16.89 p/Share	5,000 Added 6.56%	71,270 Common Stock
Sep 02 2025	SELL Open market or private sale	$160,500 $32.1 p/Share	5,000 Reduced 4.94%	96,270 Common Stock

Sep 02 2025	BUY Exercise of conversion of derivative security	$84,450 $16.89 p/Share	5,000 Added 4.7%	101,270 Common Stock
Aug 22 2025	SELL Open market or private sale	$912,900 $30.43 p/Share	30,000 Reduced 31.16%	66,270 Common Stock
Aug 22 2025	BUY Exercise of conversion of derivative security	$506,700 $16.89 p/Share	30,000 Added 23.76%	96,270 Common Stock
Aug 20 2025	SELL Open market or private sale	$189,436 $29.18 p/Share	6,492 Reduced 8.92%	66,270 Common Stock
Mar 19 2025	SELL Open market or private sale	$86,767 $34.5 p/Share	2,515 Reduced 3.36%	72,233 Common Stock
Feb 20 2025	BUY Grant, award, or other acquisition	-	43,000 Added 36.52%	74,748 Common Stock
Feb 03 2025	SELL Open market or private sale	$195,350 $39.07 p/Share	5,000 Reduced 13.61%	31,748 Common Stock
Feb 03 2025	BUY Exercise of conversion of derivative security	$84,450 $16.89 p/Share	5,000 Added 11.98%	36,748 Common Stock
Jan 07 2025	BUY Exercise of conversion of derivative security	$49,100 $19.64 p/Share	2,500 Added 7.3%	31,748 Common Stock
Jan 03 2025	SELL Open market or private sale	$781,350 $52.09 p/Share	15,000 Reduced 33.9%	29,248 Common Stock
Jan 03 2025	BUY Exercise of conversion of derivative security	$253,350 $16.89 p/Share	15,000 Added 25.32%	44,248 Common Stock
Oct 03 2024	SELL Open market or private sale	$785,306 $54.63 p/Share	14,375 Reduced 33.52%	28,507 Common Stock
Oct 03 2024	BUY Exercise of conversion of derivative security	$242,793 $16.89 p/Share	14,375 Added 25.11%	42,882 Common Stock
Jul 03 2024	SELL Open market or private sale	$645,006 $44.87 p/Share	14,375 Reduced 33.52%	28,507 Common Stock
Jul 03 2024	BUY Exercise of conversion of derivative security	$242,793 $16.89 p/Share	14,375 Added 25.11%	42,882 Common Stock
Jun 24 2024	SELL Open market or private sale	$434,434 $45.73 p/Share	9,500 Reduced 25.48%	27,786 Common Stock
Jun 24 2024	BUY Exercise of conversion of derivative security	$160,455 $16.89 p/Share	9,500 Added 20.31%	37,286 Common Stock
Apr 15 2024	SELL Open market or private sale	$639,256 $44.47 p/Share	14,375 Reduced 34.1%	27,786 Common Stock

Dana Pizzuti

Chief Med and Dev Officer

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRNX shares.

Notify only if

Value

Insider Trading

Get notified when an Crinetics Pharmaceuticals, Inc. insider buys or sells CRNX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Crinetics Pharmaceuticals, Inc.

Track Activities on CRNX

Account